Oncology Grand Rounds Series: Part 3 — Locally Advanced Non-Small Cell Lung Cancer

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee.

1.6 contact hours

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CNE credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CNE evaluation
CNE information and faculty disclosures
Select publications
PowerPoint slides

Introduction
Program overview: Dr Love
Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting
Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis
Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease
Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior
Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease
Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis
Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation
Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy